Evercore ISI Group Maintains Outperform on Ascendis Pharma, Raises Price Target to $329
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $324 to $329.